OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer
Lan Sun, Lingyue Gao, Yingxi Zhao, et al.
Recent Patents on Anti-Cancer Drug Discovery (2022) Vol. 18, Iss. 4, pp. 506-516
Closed Access | Times Cited: 12
Lan Sun, Lingyue Gao, Yingxi Zhao, et al.
Recent Patents on Anti-Cancer Drug Discovery (2022) Vol. 18, Iss. 4, pp. 506-516
Closed Access | Times Cited: 12
Showing 12 citing articles:
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC
Wenjing Liu, Lin Wang, Feng-Mei Zhou, et al.
Drug Resistance Updates (2023) Vol. 70, pp. 100987-100987
Open Access | Times Cited: 32
Wenjing Liu, Lin Wang, Feng-Mei Zhou, et al.
Drug Resistance Updates (2023) Vol. 70, pp. 100987-100987
Open Access | Times Cited: 32
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma
Qian Liang, Miaomiao Gong, Jing-Hua Zou, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100957-100957
Open Access | Times Cited: 13
Qian Liang, Miaomiao Gong, Jing-Hua Zou, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100957-100957
Open Access | Times Cited: 13
The advancements and prospective developments in anti-tumor targeted therapy
Guorui Leng, Baorong Duan, Junjie Liu, et al.
Neoplasia (2024) Vol. 56, pp. 101024-101024
Open Access | Times Cited: 4
Guorui Leng, Baorong Duan, Junjie Liu, et al.
Neoplasia (2024) Vol. 56, pp. 101024-101024
Open Access | Times Cited: 4
Epigenetic code underlying EGFR-TKI resistance in non-small-cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies
Xin Yao, Chundi Gao, Changgang Sun, et al.
Drug Discovery Today (2025), pp. 104321-104321
Closed Access
Xin Yao, Chundi Gao, Changgang Sun, et al.
Drug Discovery Today (2025), pp. 104321-104321
Closed Access
RNA methyltransferase METTL16: from molecular mechanisms to therapeutic prospects in cancers
Zhuozheng Shi, Xiankui Cao, Yiming Ma, et al.
Cancer Letters (2025), pp. 217698-217698
Closed Access
Zhuozheng Shi, Xiankui Cao, Yiming Ma, et al.
Cancer Letters (2025), pp. 217698-217698
Closed Access
Multilevel Mechanisms of Cancer Drug Resistance
Małgorzata Roszkowska
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12402-12402
Open Access | Times Cited: 3
Małgorzata Roszkowska
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12402-12402
Open Access | Times Cited: 3
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Defa Wu, Qian Sun, Hongjun Tang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101176-101176
Closed Access | Times Cited: 1
Defa Wu, Qian Sun, Hongjun Tang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101176-101176
Closed Access | Times Cited: 1
In silico resources help combat cancer drug resistance mediated by target mutations
Yuanqin Huang, Shuang Wang, Dao-Hong Gong, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103686-103686
Closed Access | Times Cited: 2
Yuanqin Huang, Shuang Wang, Dao-Hong Gong, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103686-103686
Closed Access | Times Cited: 2
HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing
Jie Liu, Wei Wang, K Wang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Jie Liu, Wei Wang, K Wang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance
Yaquan Cao, Chunli Wu, Liying Ma
Journal of Biochemical and Molecular Toxicology (2023) Vol. 38, Iss. 1
Closed Access | Times Cited: 1
Yaquan Cao, Chunli Wu, Liying Ma
Journal of Biochemical and Molecular Toxicology (2023) Vol. 38, Iss. 1
Closed Access | Times Cited: 1
Editorial: Tumor microenvironment and cancer therapy
Yi Xie, Jindong Xie, Pranav Gupta, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access
Yi Xie, Jindong Xie, Pranav Gupta, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access
